Latest Peplin news



news 

01-Feb-10

LEO Pharma's PEP005 Meets Primary Endpoint in Phase III Trial for Pre-Cancerous Skin Condition read more

21-Dec-09

Positive Results for LEO Pharma's Phase III Actinic Keratosis Trials on the Face and Scalp read more

12-Nov-09

Letter to our CDI Holders read more


About Peplin

Peplin focuses on researching, developing and commercializing innovative drugs in medical dermatology.

Peplin is a wholly-owned subsidiary of LEO Pharma, an independent, research-based pharmaceutical company based in Denmark.  Peplin is headquartered in Emeryville, California with operations in Brisbane, Queensland, Australia and a manufacturing facility in Southport, Queensland.

Our core technology is a novel class of naturally occurring compounds which show significant potential as anti-cancer agents for a wide range of human cancers. The lead compound in this technology, PEP005 (ingenol mebutate), or PEP005, is in Phase 3 trials for the treatment of actinic keratosis (AK), sometimes known as solar keratosis or sunspots, a common pre-cancerous lesion.

Peplin retains sole rights to develop and market PEP005 and has extensive international patent coverage over its technologies.

Peplin at a glance


Parent Company

LEO Pharma, Denmark 

Offices

Emeryville, California, USA
Brisbane, Queensland, Australia

Year Founded

1998

Trading Symbol

Not applicable, wholly owned subsidiary of LEO Pharma, a private company

US Incorporation

2007 in Delaware

Employees (global)

40 (approx)

Current Stage of Development

Phase 3

Email Us

Email: info@peplin.com